AstraZeneca Receives FDA Approval for Tezspire in Pediatric Severe Asthma

AstraZeneca today announced that the FDA has approved Tezspire (tezepelumab-ekko) as an add-on maintenance treatment for children aged 6 to 11 years with severe asthma. In the Phase 3 SUNRISE trial, Tezspire demonstrated significant reductions in annualized asthma exacerbation rates in pediatric patients with severe asthma. The safety profile was consistent with the known profile of Tezspire in adults. This approval expands Tezspire's use into the pediatric population, providing children with severe asthma a new biologic treatment option. Tezspire targets TSLP, a key upstream cytokine in asthma pathogenesis.